Skip to content

Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)

Peripheral Artery Disease: Gated P-31 Magnetic Resonance Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03723473
Acronym
SPECTROAOMI
Enrollment
40
Registered
2018-10-29
Start date
2019-02-13
Completion date
2025-04-30
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Occlusive Diseases

Keywords

Peripheral Arterial Occlusive Disease (PAOD), Phosphorus-31, Magnetic Resonance Imaging (MRI), Spectroscopy, Revascularization, Claudication with surgical planning

Brief summary

To explore the reliability of P-31 MR spectroscopy mitochondrial function in patients with peripheral arterial occlusive disease.

Detailed description

Peripheral arterial occlusive disease (PAOD) is defined as the partial or total obstruction of one or more lower extremity arteries, most often of atherosclerotic origin. It is a common disease whose 5-years mortality is near 30%.The positive diagnosis is based on clinical examination and measurement of the ankle-brachial index (ABI), which is the ratio of systolic pressure of ankle and brachial systolic pressure. The threshold value for the diagnosis is \<0.90. Physiopathologically, mitochondria have the predominant role of providing the ATP necessary for the energetic needs of myocytes, which increase drastically during muscle contraction during exercise. This energy production is of course conditioned by the availability of oxygen. In patients with PAOD, the decrease in blood flow secondary to significant stenosis has the direct consequence of disrupting oxygen delivery to distal muscles and thus limiting muscular performance. Because mitochondrial respiration is the only metabolic pathway capable of providing the energy needed to sustain an effort of several minutes, intermittent claudication in PAOD has logically been related to a hemodynamic mechanism of intermittent muscle hypoperfusion. Recently, an increasing number of histological or functional studies have suggested that episodes of ischemia-reperfusion could induce mitochondrial dysfunction. Medical treatment of patients frequently includes statins while a direct deleterious effect on mitochondrial function has been suspected, inducing a deterioration of the muscular oxidative capacity which would increase the factors hemodynamics and may accumulate in mitochondrial myopathy. In the light of these elements, it is clear that there would be a benefit in being able to distinguish and quantify 1) the part of the reduction of mitochondrial activity secondary to the hemodynamic factor alone due to a decreased muscle perfusion 2) the mitochondrial involvement (mitochondriopathy) potentially induced by oxidative stress in PAOD. 2 sub-groups are distinguished to identify the statin-induced mitochondrial dysfunction.

Interventions

DEVICEMagnetic Resonance Imaging (MRI)

MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.

Sponsors

Dr MAYER Ronald A. Department of Physiology, Michigan State University
CollaboratorUNKNOWN
Dr SLADE Jill M. Department of Osteopathic Manipulative Medicine, Michigan State University
CollaboratorUNKNOWN
Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Peripheral arterial occlusive disease (PAOD) with claudication and surgery planning with proximal lesion (iliac or femoral (x-ray angiography or CT or MRA) and no distal lesions (doppler) * ABI\<0.90 or \>1.30 * signed consent form * health insurance coverage

Exclusion criteria

* Contraindication in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part, claustrophobia * critical ischemia \>15 days * Type 1 or 2 diabetes * weight \>200kg * non stabilized hypertension * beta-blockers * non-atherosclerotic vascular occlusive disease (Buerger disease, Takayasu disease, venous disease, trapped popliteal artery etc..) * Neurological pathology/non-voluntary contraction

Design outcomes

Primary

MeasureTime frameDescription
Muscle phosphocreatine (PCr) recovery time constantDuring the MRI procedureMuscle phosphocreatine (PCr) recovery time constant (index of muscle aerobic capacity) after gated low-intensity exercise (2maximum voluntary isometric dorsiflexion contractions, at 30s intervals for 8min (total contractions = 15)

Secondary

MeasureTime frameDescription
Muscular volume and contentDuring the MRI procedureimpact of muscular volume and content. Measures will be extracted from DIXON and T2\* MRI
PCr recovery time constantDuring the MRI procedureimpact of statin treatment on PCr recovery time constant

Countries

France

Contacts

Primary ContactPierre CROISILLE, PhD
croisille@creatis.insa-lyon.fr(0)477127584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026